A Study of LY3502970 in Participants With Type 2 Diabetes

NCT04426474 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety of the experimental drug LY3502970 in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 68 people

Who can join Ages 18–70 · all sexes

Timeline Started 2020-10 · est. completion 2021-07

Where 6 sites · Germany, United States

What this study is testing ClinicalTrials.gov NCT04426474 ↗

Description as written by the study sponsor.

The main purpose of this study is to learn more about the safety of LY3502970 and any side effects that might be associated with it. Blood tests will be done to measure how much LY3502970 is in the bloodstream, how long it takes the body to eliminate it, and how it affects blood sugar. Participation could last up to 18 weeks and may include up to 14 visits (including three overnight stays) in the study center.

Treatments tested

LY3502970 Drug

Administered orally.
Placebo Drug

Administered orally.

Main thing measured	Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04426474 ↗